COLLEGIUM PHARMACEUTICAL, INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K)adopted, amended, orterminated by our directors and officers during the three months ended December 31, 2025:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name · Title · Action · Effective Date · Rule 10b5-1 · Non-Rule 10b5-1 · Scheduled Expiration Date of Trading Plan(1) · Maximum Shares Subject to Trading Plan | ||||||
| David Dieter | Executive Vice President, General Counsel and Corporate Secretary | Adoption | December 8, 2025 | X | March 31, 2026 | 28,683 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | Adoption | November 17, 2025 | X | October 30, 2026 | 55,175 |
(1) A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement.
Each Rule 10b5-1 trading arrangement described above was adopted in compliance with Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.